Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field

Sep 12 2017

• By Joseph Haas

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.

Related Content

Asunaprevir NDA Withdrawal Likely To Mean Daclatasvir Delay

Oct 07 2014

J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV

Nov 14 2016

AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

Aug 03 2017

J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV

Sep 09 2016

Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV

Feb 24 2017

INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow

Aug 01 2016

Related Companies

Merck & Co., Inc.

Johnson & Johnson

Gilead Sciences, Inc.

Achillion Pharmaceuticals, Inc.

Alios BioPharma

Bristol Myers Squibb Company

AbbVie Inc.

Medivir AB

Additional Topics

Business Strategies Deals Commercial Infectious Diseases BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.